Table 3.

Factors Associated with Response

	N	% Response	P
Diagnosis
Lymphoid malignancy	13	38%
Myeloid malignancy	23	48%	0.59
Disease status at DLI
No evidence of disease	13	38%
Evidence of disease	23	48%	0.59
CD3 donor chimerism at DLI1
≤27%	18	37%
>27%	17	56%	0.25
Time from HCT to study intervention
<100 days	21	57%
>100 days	15	27%	0.07
DLI dose
1×107 CD3/kg	26	54%
3×107 CD3/kg	10	20%	0.07
Donor
Related	17	47%
Unrelated	19	42%	0.77
Patient age at treatment intervention*
≤56 years	18	61%
>56 years	18	28%	0.04
Donor age at HCT*
≤45 years	17	41%
>45 years	16	44%	0.88
ANC count at DLI (×103/μL)*
≤ 2.15	17	29%
>2.15	17	59%	0.08
Lymphocyte count at DLI (×103/μL)*
≤0.46	16	25%
>0.46	16	63%	0.03
Immunosuppression after DLI
No	30	47%
Yes	6	33%	0.55

^*Divided at median